%0 Journal Article
%T Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia
%A Angela Goldsberry
%A Chad Hoyle
%A Clementina Mesaros
%A Colin Meyer
%A George R. Wilmot
%A Ian A. Blair
%A Jennifer Farmer
%A Lauren Hauser
%A Martin B. Delatycki
%A Megan O'Grady
%A Melanie Chin
%A Michael G. McBride
%A Nathaniel Snyder
%A Paola Giunti
%A Qing Qing Wang
%A S. H. Subramony
%A Susan Perlman
%A Sylvia Boesch
%A Theresa Zesiewicz
%A Wolfgang Nachbauer
%J Archive of "Annals of Clinical and Translational Neurology".
%D 2019
%R 10.1002/acn3.660
%X Previous studies have demonstrated that suppression of Nrf2 in Friedreich ataxia tissues contributes to excess oxidative stress, mitochondrial dysfunction, and reduced ATP production. Omaveloxolone, an Nrf2 activator and NFİ\kB suppressor, targets dysfunctional inflammatory, metabolic, and bioenergetic pathways. The doseİ\ranging portion of this Phase 2 study assessed the safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia patients (NCT02255435)
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331199/